Back to Search
Start Over
Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma
- Publication Year :
- 2020
- Publisher :
- American Society of Hematology, 2020.
-
Abstract
- Key Points We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model. Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.
- Subjects :
- 0301 basic medicine
Extramural
Hepatosplenic T-cell lymphoma
business.industry
T cell
EZH2
Receptors, Antigen, T-Cell, gamma-delta
Hematology
macromolecular substances
medicine.disease
Lymphoma, T-Cell
Lymphoma
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
030220 oncology & carcinogenesis
Cancer research
medicine
Humans
Exceptional Case Report
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....deac2d7bf630e6db5e3de15f6b3f8e87